SEARCH

SEARCH BY CITATION

References

  • Bateman R. J., Aisen P. S., De Strooper B. et al. (2011) Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1.
  • Borgegard T., Gustavsson S., Nilsson C. et al. (2012) Alzheimer's disease: presenilin 2-sparing gamma-secretase inhibition is a tolerable Abeta peptide-lowering strategy. J. Neurosci. 32, 1729717305.
  • Campion D., Dumanchin C., Hannequin D. et al. (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664670.
  • Chavez-Gutierrez L., Bammens L., Benilova I. et al. (2012) The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 22612274.
  • Cruts M., Theuns J. and Van Broeckhoven C. (2012) Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 33, 13401344.
  • De Jonghe C., Esselens C., Kumar-Singh S., Craessaerts K., Serneels S., Checler F., Annaert W., Van Broeckhoven C. and De Strooper B. (2001) Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect A beta secretion and APP C-terminal fragment stability. Hum. Mol. Genet. 10, 16651671.
  • De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K. and Van Leuven F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387390.
  • Eckman C. B., Mehta N. D., Crook R. et al. (1997) A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum. Mol. Genet. 6, 20872089.
  • Eckman E. A., Reed D. K. and Eckman C. B. (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 276, 2454024548.
  • Edwards-Lee T., Ringman J. M., Chung J. et al. (2005) An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology 64, 377379.
  • Forloni G., Terreni L., Bertani I. et al. (2002) Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol. Aging 23, 957976.
  • Franberg J., Svensson A. I., Winblad B., Karlstrom H. and Frykman S. (2011) Minor contribution of presenilin 2 for gamma-secretase activity in mouse embryonic fibroblasts and adult mouse brain. Biochem. Biophys. Res. Commun. 404, 564568.
  • Fraser P. E., Nguyen J. T., Inouye H., Surewicz W. K., Selkoe D. J., Podlisny M. B. and Kirschner D. A. (1992) Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry 31, 1071610723.
  • Games D., Adams D., Alessandrini R. et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523527.
  • Goate A., Chartier-Harlin M. C., Mullan M. et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704706.
  • Groves J. T., Parthasarathy R. and Forstner M. B. (2008) Fluorescence imaging of membrane dynamics. Annu. Rev. Biomed. Eng. 10, 311338.
  • Guardia-Laguarta C., Pera M., Clarimon J. et al. (2010) Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J. Neuropathol. Exp. Neurol. 69, 5359.
  • Guerreiro R. J., Baquero M., Blesa R. et al. (2010) Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol. Aging 31, 725731.
  • Haass C., Koo E. H., Mellon A., Hung A. Y. and Selkoe D. J. (1992) Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357, 500503.
  • Haass C., Lemere C. A., Capell A., Citron M., Seubert P., Schenk D., Lannfelt L. and Selkoe D. J. (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat. Med. 1, 12911296.
  • Haass C., Kaether C., Thinakaran G. and Sisodia S. (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, a006270.
  • Herl L., Thomas A. V., Lill C. M., Banks M., Deng A., Jones P. B., Spoelgen R., Hyman B. T. and Berezovska O. (2009) Mutations in amyloid precursor protein affect its interactions with presenilin/gamma-secretase. Mol. Cell. Neurosci. 41, 166174.
  • Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N. and Ihara Y. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end- specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 4553.
  • Janssen J. C., Beck J. A., Campbell T. A., Dickinson A., Fox N. C., Harvey R. J., Houlden H., Rossor M. N. and Collinge J. (2003) Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 60, 235239.
  • Jiang Y., Mullaney K. A., Peterhoff C. M. et al. (2010) Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl Acad. Sci. USA 107, 16301635.
  • Kim H. S., Kim E. M., Lee J. P. et al. (2003) C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J. 17, 19511953.
  • Kumar-Singh S., De Jonghe C., Cruts M. et al. (2000) Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum. Mol. Genet. 9, 25892598.
  • Lauritzen I., Pardossi-Piquard R., Bauer C. et al. (2012) The beta-secretase-derived C-terminal fragment of betaAPP, C99, but not Abeta, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J. Neurosci. 32, 1624316255a.
  • Lichtenthaler S. F., Wang R., Grimm H., Uljon S. N., Masters C. L. and Beyreuther K. (1999) Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 96, 30533058.
  • Lleo A. and Saura C. A. (2011) Gamma-secretase substrates and their implications for drug development in Alzheimer's disease. Curr. Top. Med. Chem. 11, 15131527.
  • Lleo A., Berezovska O., Growdon J. H. and Hyman B. T. (2004) Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am. J. Geriatr. Psychiatry 12, 146156.
  • Magrane J., Sahawneh M. A., Przedborski S., Estevez A. G. and Manfredi G. (2012) Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32, 229242.
  • McPhie D. L., Lee R. K., Eckman C. B., Olstein D. H., Durham S. P., Yager D., Younkin S. G., Wurtman R. J. and Neve R. L. (1997) Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains. J. Biol. Chem. 272, 2474324746.
  • Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K. and Matsuoka N. (2012) Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32, 20372050.
  • Morelli L., Llovera R., Gonzalez S. A., Affranchino J. L., Prelli F., Frangione B., Ghiso J. and Castano E. M. (2003) Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J. Biol. Chem. 278, 2322123226.
  • Nilsberth C., Westlind-Danielsson A., Eckman C. B. et al. (2001) The ‘Arctic’ APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887893.
  • Oster-Granite M. L., McPhie D. L., Greenan J. and Neve R. L. (1996) Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J. Neurosci. 16, 67326741.
  • Page R. M., Gutsmiedl A., Fukumori A., Winkler E., Haass C. and Steiner H. (2010) Beta-amyloid precursor protein mutants respond to gamma-secretase modulators. J. Biol. Chem. 285, 1779817810.
  • Pera M., Alcolea D., Sanchez-Valle R. et al. (2012) Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol. 125, 201213.
  • Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y. et al. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J. Neurosci. 25, 436445.
  • Raux G., Guyant-Marechal L., Martin C., Bou J., Penet C., Brice A., Hannequin D., Frebourg T. and Campion D. (2005) Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J. Med. Genet. 42, 793795.
  • Sastre M., Steiner H., Fuchs K., Capell A., Multhaup G., Condron M. M., Teplow D. B. and Haass C. (2001) Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2, 835841.
  • Sato T., Dohmae N., Qi Y. et al. (2003) Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J. Biol. Chem. 278, 2429424301.
  • Saura C. A., Chen G., Malkani S. et al. (2005) Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J. Neurosci. 25, 67556764.
  • Schneider C. A., Rasband W. S. and Eliceiri K. W. (2012) NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671675.
  • Tan J., Mao G., Cui M. Z., Kang S. C., Lamb B., Wong B. S., Sy M. S. and Xu X. (2008) Effects of gamma-secretase cleavage-region mutations on APP processing and Abeta formation: interpretation with sequential cleavage and alpha-helical model. J. Neurochem. 107, 722733.
  • Tsubuki S., Takaki Y. and Saido T. C. (2003) Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361, 19571958.
  • Vom Berg J., Prokop S., Miller K. R. et al. (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 18, 18121819.
  • Yankner B. A., Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L. and Neve R. L. (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417420.
  • Zekanowski C., Styczynska M., Peplonska B. et al. (2003) Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp. Neurol. 184, 991996.